

Drugs R D (2013) 13:241–242
DOI 10.1007/s40268-013-0033-5

ACKNOWLEDGEMENT TO REFEREES

© Springer International Publishing Switzerland 2013

Dear Reader

As we reach the final issue of *Drugs in R&D* for 2013, we hope that you have found the articles published throughout the year to be interesting and informative. *Drugs in R&D* is the only fully open access journal published by Adis, and the editor and publishing staff have appreciated the high quality of content contributed to the journal this year. The publishing schedule for 2014 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.

The Adis journals portfolio as a whole saw impressive Impact Factor gains, with flagship journals continuing to increase their citations—*Drugs* raised its Impact Factor to 4.633, with *Clinical Pharmacokinetics* and *Sports Medicine* also seeing significant rises to 6.109 and 5.237, respectively. *Pharmacoeconomics* remains the number one journal in its field, and *The Patient: Patient-Centered Outcomes Research* saw an increase of more than 170 % in its Impact Factor to 1.565, only one year after first appearing in the Journal Citation Reports®.

2013 saw the successful integration of the Adis portfolio of journals into the Springer production systems and custom-built platforms (SpringerLink, Springer for R&D, and Springer for Hospitals & Health). We are confident that our authors and subscribers benefit from improved discoverability, mobile optimisation and robust delivery of content on these platforms; and Springer production capacity has allowed us to increase the number of articles published whilst reducing submission-to-publication times to a uniform 2–3 months across the portfolio.

Looking ahead to 2014, the Adis portfolio will continue to grow the amount of content published while maintaining high standards. The number of Adis titles will also increase as existing quality Springer journals are brought under the Adis brand—*Advances in Therapy, Targeted Oncology*, and the *European Journal of Drug Metabolism and Pharmacokinetics*. Adis are also committed to fostering Open Access publication: all Adis titles offer the Springer Open Choice option and we are adding a further ten fully Open Access titles in specific therapy areas such as *Diabetes Therapy, Cardiology and Therapy* and *Dermatology and Therapy*, previously published under the Springer Healthcare imprint. Information about the portfolio can be found on Springer.com/Adis.

We would like to thank all the authors who have contributed articles to *Drugs in R&D* in the last 12 months. They have generously set aside time in their busy schedules to prepare content, and without their hard work and diligence we would not have been able to publish the journal. The quality of published articles also reflects the significant time and effort dedicated by the peer reviewers, who ensure that we continue to publish content of the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals who acted as referees for articles in *Drugs in R&D* in 2013:

David F. Archer, USA
Shahram Bahmanyar, Sweden
Emad B. Basalious, Egypt
Antonio Bellasi, Italy
Fulvio Bertolotto, Italy
G.A. Block, USA
Samuel W. Boellner, USA
Ann Catherine Childress, USA
Arrigo F.G. Cicero, Italy
Daniel F. Connor, USA
Laszlo Endrenyi, Canada
Oscar Fernandez, Spain
D. Gatti, USA
C. Giannarelli, Italy
David J. Greenblatt, USA
Manuel Haschke, Switzerland
John Haughney, UK
D. Heng, Singapore
A. Hill, New Zealand
L. Holmvang, Denmark
Katsuomi Iwakura, Japan
Svein I. Johannessen, Norway
N.J. Kachuck, USA
A. Kahokehr, New Zealand

Asim Kalkan, Turkey
James Ker, South Africa
M. Liedtke, USA
S. Mallaysamy, India
M. Martins, Brazil
Doreen Matsui, Canada
Andrew J. McLachlan, Australia
D. Miller, USA
F. Morabito, Italy
Isamu Okamoto, Japan
J.S. Oxford, UK
Deborah Pearson, USA
A. Pottegaard, Denmark
M. Ranieri, Italy
Francois Roubille, France
S.M. Said, Germany
K. Sampathkumar, India
C. Schultz, USA
R. Schulz, Germany
Carlos Sostres, Spain
M. Symillides, Greece
Takeshi Takami, Japan
Laura E. Targownik, Canada
Ulrich U. Tebbe, Germany

D. Torok, Hungary
Dietmar Trenk, Germany
Tsukasa Uno, Japan
T. VanCaillie, Australia
Roger K. Verbeeck, Belgium

Carolyn Westhoff, USA
Mario Wurglics, Germany
Recep Yildizhan, Turkey
Mohammad Urooj Zafar, USA

Drugs in R&D provides a valuable open access option for the publication of research from all stages of drug development. We would like to remind you to keep *Drugs in R&D* in mind when deciding where to submit your research. We also welcome comment from our readers on any of our articles.

We look forward to your continued support of the journal in 2014 and to bringing you first-class content from around the globe. With best wishes from the staff of *Drugs in R&D* and all at Adis Publications.